| Total: $1,062.94 | ||||
Company |
Type Of |
Number Of |
Amount |
Investors; Placement Agents; Details |
| | ||||
Adventrx |
Private placement of stock |
14.545S |
$40 |
Accredited and institutional investors purchased the stock at $2.75 per share; ThinkEquity Partners LLC was lead placement agent; Fortis Securities LLC was co-agent (11/3) |
Akesis |
Private placement of stock and warrants |
5.85S and 0.878W |
$3.51 |
The shares were sold at $0.60 each; warrants are exercisable at the same price; $3M of the investment was provided by Avalon Ventures VII LP (11/27) |
Anesiva Inc. |
Registered direct offering |
7S |
$44.8 |
The registered stock was sold to institutional investors at $6.40 per share, the Nov. 21 closing price; Lazard Capital Markets LLC was lead placement agent; Needham & Co. LLC and Rodman & Renshaw LLC were co-agents (11/22) |
Avanir |
Private placement of stock and warrants |
5.265S and 1.053W |
$15 |
Institutional investors purcahsed the stock at $2.85 per share; the one-year warrants are exercisable at $3.30 per share; Rodman & Renshaw LLC was placement agent (11/3) |
Biofusion plc |
Private placement of stock |
5.35S |
£7.75 ($15.3) |
Shares were sold at 145 pence each in a deal fully underwritten by Nomura Code Securities (11/30) |
BioMS |
Private placement of stock and warrants |
6.129S and 3.065W |
C$20.9 ($18.3) |
Units consisting of one share and one-half warrant were sold at C$3.41 each; full four-year warrants are exercisable at C$4 per share; Versant Partners Inc. and Rodman & Renshaw were co-lead placement agents; Fondsfinans ASA was co-agent (11/24) |
BioTie |
Private placement of stock |
25.49S |
€13 ($17.2) |
Investors including Pequot Capital, Dreadnought Finance Oy, Thominvest Oy and SITRA purchased the stock at €0.51 per share; another €7.5M could be added to the deal by retail investors (11/30) |
Cangene |
Bought-deal financing |
4.375S |
C$35.4 ($31) |
Underwriters led by GMP Securities LP and including TD Securities Inc., Scotia Capital Inc. and Sprott Securities Ltd. purchased the stock at C$8.10 per shares; totals do not include 5.625M shares sold in the deal by existing shareholders (11/21) |
Clinuvel |
Rights issue and private placement |
91.4S |
A$35.2 ($27.1) |
Clinuvel raised A$30.5M in a rights issue and A$4.7M in a private placement; shares were sold at A$0.385 in each deal (11/1) |
CollaGenex |
Private placement of stock |
3.5S |
$45.5 |
Institutional and other investors are purchasing the registered shares at $13 each, a 2% discount to the prior day's close; Lazard Capital Markets LLC was placement agent (11/16) |
Corcept |
Private placement of stock |
3S |
$3 |
Paperboy Ventures LLC led the financing, which included Sutter Hill Ventures and three members of Corcept's board (11/15) |
Crucell NV |
Private placement of stock |
ND |
€80 ($105) |
The funds were raised as part of Crucell's acquisition of SBL Vaccin AB; specific details on the financing were not disclosed (11/21) |
Cytogen |
Private placement of stock and warrants |
7.09S and 3.546W |
$20 |
Institutional investors purchased units at $2.82 each; the five-year warrants are exercisable at $3.32 per share (11/7) |
Discovery |
Private placement of stock and warrants |
4.6S and 2.3W |
$10 |
One institutional investor purchased the stock at $2.16 per share, a 5% discount to a five-day average; the five-year warrants are exercisable at $3.18 per share; Jefferies & Co. Inc. was placement agent (11/22) |
Dyadic |
Private placement of stock and warrants |
2.787S and 0.557W |
$13 |
The stock was sold at $4.68 per share; the 3.5-year warrants are exercisable, after 180 days, at $6.33 per share; Cowen and Co. LLC was placement agent (11/20) |
Hollis-Eden |
Private placement of stock and warrants |
4S and 0.8W |
$26 |
The registered shares were sold at $6.50 each; the four-year warrants are exercisable at $8.75 per share; Rodman & Renshaw LLC was lead placement agent; Canaccord Adams Inc. was co-agent (11/8) |
Introgen |
Private placement of stock |
1.32S |
$6.1 |
An institutional investor purchased the registered shares; Mulier Capital was placement agent (11/7) |
Lumera |
Private placement of stock and warrants |
2.825S and 0.424W |
$16.95 |
The shares were sold at $6 each; the five-year war- rants are exercisable at $6.25 per share; the investment was led by Robert W. Baird & Co. (11/8) |
Metabasis |
Committed equity facility |
N/A |
N/A |
Kingsbridge Capital Ltd. committed to buy up to $50M in Metabasis stock over three years at a dis-count of 6% to 10%; Metabasis will determine the timing and amount of any sale (11/2) |
Migenix Inc. |
Bought-deal financing |
16.75U |
C$10 ($8.74) |
A Canadian investment dealer purchased the units at C$0.60 per unit; each consists of one common share and one-half of a warrant; each whole war- rant is exercisable at C$0.80 per share (11/16) |
Millennium |
Sale of convertible notes |
N/A |
$250 |
The 2.25% notes are due in 2011; they are convertible into common shares at an intial price of $15.47 per share; Morgan Stanley & Co. Inc. and JP Morgan Securities Inc. are joint managers for the deal; totals include their purchase of $25M in the notes per an overallotment option (11/9) |
Neurochem |
Private |
N/A |
$42.09 |
The 6% notes due in 2026 carry a conversion premium of 20%, initially $19.72 per share; totals include the purchase of $2.085M in notes by UBS Securities LLC per its overallotment option (11/3) |
Neuro-Hitech |
Private placement of stock and warrants |
0.605S and 0.302W |
$3.1 |
Up to 604,878 shares and 302,439 warrants are being sold; the exact number of shares and warrants will equal the greater of $5.125 per share or a 20% discount to a 20-day trading average prior to its acquisition of Q-RNA Inc.; the warrants will be exercisable at $7 per share (11/17) |
Nymox |
Private |
ND |
$13 |
Institutional investors purchased the shares at a 3% discount to the market price; the number of shares and the price were not disclosed (11/29) |
Pipex |
Private placement of stock and warrants |
13.7S and 6.8W |
$13.7 |
Accredited Venture Capital LLC provided $4.5M in funding prior to Pipex's merger with Sheffield Pharmaceuticals Inc.; the second deal totaling $9.2M involved the sale of 13.7M shares and 6.8M warrants exercisable at $0.74 per share (11/28) |
Prana |
Private |
21.8S and 4.35W |
A$7.8 ($6.1) |
Shares are being purchased at A$0.357 per share (about $2.80 per ADR); the options are exercisable at A$0.446 per share (about $3.40 per ADR) (11/21) |
Protox |
Private placement of stock and warrants |
18.35S and 9.175W |
C$9.17 ($8) |
Units consisting of one share and half a warrant were sold at C$0.50 each; each one-year warrant is exercisable at C$0.65 per share; Jennings Capital Inc. and Canaccord Capital Corp. co-led the deal (11/29) |
Regeneron |
Private placement of stock |
7.6S |
$175 |
Morgan Stanley & Co. Inc. purchased the registered shares at $23.03 each (11/13) |
SR Pharma pl (UK; AIM:SPA) |
Private placement of stock |
20S |
£3.8 ($7.2) |
Institutional investors, including some existing shareholders, purchased the stock at 19 pence per share (11/6) |
Tm Bioscience |
Credit facility |
N/A |
N/A |
Laurus Master Fund Ltd. provided the 7% credit facility, payable initially with stock at C$0.71 per share; the facility matures on Aug. 31, 2007 (11/28) |
TopoTarget |
Private placement of stock |
4.153S |
DKK126.7 ($22.5) |
The stock was sold at DKK30.5 per share; ABN AMRO Rothschild and Handelsbanken Capital Markets were placement agents (11/28) |
Vasogen Inc. |
Private placement of stock and warrants |
43.2S and 21.6W |
$20.3 |
Units consisting of a share and half a warrant were sold at $0.47 each; 80% of the warrants are exercisable for five years at $0.63 per share; 20% are exercisable for six months at $0.53 per share; Rodman & Renshaw LLC was placement agent (11/9) |
Virax |
Rights issue and placement |
13.5S |
A$2.36 ($1.85) |
Shareholders subscribed to A$0.56M in stock, and A$1.80 million was committed by way of shortfall placement agreements with Tricom Equities Ltd. (11/9) |
Vivus Inc. |
Registered direct offering |
9.6S |
$33.6 |
The registered shares were purchased at $3.50 each; Caxton Advantage Life Sciences Fund LP led the financing, which also included Euclid SR Partners, OrbiMed Advisors LLC, Franklin Templeton Investments and Quogue Capital LLC (11/20) |
| | ||||
Notes: | ||||
This chart does not include real estate or manufacturing plant financings, or debt deals done to replace existing debt. | ||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. | ||||
Currency conversions are based on exchange rates at the time of the deal. | ||||
N/A = Not applicable; ND = Not disclosed. | ||||
AIM = Alternative Investment Market; AMEX = American Stock Exchange; ASX = Australian Stock Exchange; CDNX = Canadian Venture Exchange; CSE = Copenhagen Stock Exchange; HSE = Helsinki Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSX = Toronto Stock Exchange. | ||||
